Carcinoma of Unknown Primary¶
Chapter 97 | Part 12: Oncology and Hematology
KEY CLINICAL POINTS¶
- CUP is a biopsy-proven malignancy with an undetermined primary site, accounting for 3–5% of all cancers globally.
- Advanced imaging, immunohistochemistry (IHC), and molecular profiling are critical for diagnosis and treatment planning.
- Treatment is tailored based on histology, molecular markers, and clinical context, with chemotherapy, targeted therapies, and radiation as mainstays.
1. DEFINITION & OVERVIEW¶
Carcinoma of unknown primary (CUP) is a malignancy with an undetermined primary site despite thorough diagnostic evaluation. It is one of the 10 most frequently diagnosed cancers globally. CUP may arise from tumors that regress after metastasis or remain undetected due to their small size. The 'unknown' designation is increasingly challenged by advanced diagnostics, including genomic and proteomic tools.
Table 97-1: Major Histologies in Carcinoma of Unknown Primary¶
| HISTOLOGY | PROPORTION, % |
|---|---|
| Well to moderately differentiated adenocarcinoma | 60 |
| Squamous cell cancer | 5 |
| Poorly differentiated adenocarcinoma, poorly differentiated carcinoma | 30–35 |
| Neuroendocrine | 2 |
| Undifferentiated malignancy | 3 |
1.1 Diagnostic Challenges¶
CUP is often misdiagnosed due to the lack of a primary site. Advances in imaging, IHC, and molecular profiling have improved diagnostic accuracy, but challenges remain in differentiating CUP from cancers with known primaries (e.g., lymphomas, melanomas).
1.2 Clinical Presentation¶
CUP can present with diverse symptoms, including bone pain, hypercalcemia, and metastatic lesions. Liver is a common site of presentation, with intrahepatic cholangiocarcinoma (ICC) often misdiagnosed as CUP.
2. EPIDEMIOLOGY¶
CUP accounts for 3–5% of all malignancies, with a declining incidence. It affects all age groups, including adolescents and young adults. Risk factors include prior surgeries, family history of hereditary cancers, and demographic factors. The incidence of ICC is increasing, while CUP incidence is declining.
2.1 Demographics¶
CUP is more common in adults, with no specific gender predilection. Adolescents and young adults may present with unique patterns, such as bone metastases or testicular germ cell tumors.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
CUP may arise from tumors that regress after seeding metastases or remain undetected due to their small size. The immune system may contain the primary tumor, leading to metastatic spread. Molecular profiling reveals genomic alterations (e.g., TP53, KRAS, CDKN2A) and potential driver mutations.
3.1 Molecular Mechanisms¶
Genomic profiling identifies alterations in RTK/Ras/MAPK pathways (adenocarcinoma CUP) and other mutations (e.g., ARID1A, NTRK fusions). These findings guide targeted therapies.
4. CLINICAL FEATURES¶
Symptoms include bone pain, hypercalcemia, and metastatic lesions. Complications include fractures, poor prognosis, and organ-specific manifestations (e.g., liver metastases, peritoneal carcinomatosis).
4.1 Complications¶
Bone metastases may lead to fractures, while hypercalcemia requires urgent management. Peritoneal carcinomatosis (PPSC) mimics ovarian cancer but lacks a primary ovarian tumor.
5. DIFFERENTIAL DIAGNOSIS¶
CUP must be differentiated from cancers with known primaries (e.g., lymphomas, melanomas, sarcomas). ICC and other cancers with distinct histology and management guidelines are excluded from CUP classification.
5.1 Confounding Diagnoses¶
Intrahepatic cholangiocarcinoma (ICC) is often misdiagnosed as CUP. Molecular profiling helps distinguish these entities.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes imaging (CT, MRI, PET), IHC, and molecular profiling. Serum markers (e.g., PSA, CA-125) are nonspecific but aid in narrowing the differential.
Table 97-2: Select Immunohistochemical Stains for CUP¶
| LIKELY PRIMARY PROFILE | COMMONLY CONSIDERED IHC |
|---|---|
| Breast | ER, GCDFP-15, mammaglobin, HER2/neu, GATA3 |
| Lung adenocarcinoma | TTF-1, napsin A, SP-A1 |
| Germ cell | b-hCG, AFP, OCT3/4, CD30, SALL4 |
| Prostate | PSA, AMACR/P504S, NKX3-1 |
| LIKELY PRIMARY PROFILE | COMMONLY CONSIDERED IHC |
|---|---|
| Intestinal | CK7, CK20, CDX-2, CEA |
6.1 Imaging Modalities¶
Baseline IV contrast CT of chest, abdomen, and pelvis is standard. PET-CT aids in staging and biopsy guidance. MRI is used for breast and pelvic lesions.
6.2 Immunohistochemistry¶
CK7, CK20, TTF-1, and CDX-2 are key markers. IHC panels (e.g., ER, GCDFP-15, HER2) help identify potential primaries (e.g., breast, lung).
7. MANAGEMENT & TREATMENT¶
Treatment is guided by histology, molecular profiling, and clinical context. Chemotherapy (e.g., paclitaxel/carboplatin), targeted therapies (e.g., anti-EGFR), and radiation are mainstays. Molecular profiling identifies actionable mutations (e.g., NTRK fusions, MSI-H/dMMR).
Table 97-3: Treatment Algorithms for CUP¶
| CLINICAL SCENARIO | TREATMENT APPROACH |
|---|---|
| Isolated axillary adenopathy (women) | Breast MRI, hormonal therapy, surgery if positive |
| Blastic bone metastases with elevated PSA | Hormonal therapy, platinum-based chemotherapy |
| Peritoneal carcinomatosis | Cytoreductive surgery + taxane/platinum chemotherapy |
| Neuroendocrine tumors | Somatostatin analogs, sunitinib, everolimus |
7.1 Chemotherapy Regimens¶
Standard regimens include paclitaxel/carboplatin, gemcitabine/cisplatin, and irinotecan/fluoropyrimidines. Response rates range from 25–40%.
7.2 Targeted Therapies¶
NTRK inhibitors (e.g., larotrectinib), anti-EGFR agents (e.g., afatinib), and immune checkpoint inhibitors (e.g., pembrolizumab for MSI-H/dMMR) are used based on molecular profiling.
8. PROGNOSIS & COMPLICATIONS¶
Median survival for disseminated CUP is 6–10 months. Prognostic factors include performance status, LDH levels, and number of metastases. Poorly differentiated carcinomas have a worse prognosis.
8.1 Prognostic Factors¶
Performance status (ECOG), serum LDH, and metastatic burden (number of sites) are critical. Culine’s model uses these to stratify patients.
9. SPECIAL CONSIDERATIONS¶
Pregnancy, pediatrics, and elderly patients require tailored approaches. For example, women with isolated axillary nodes undergo breast MRI, while men with elevated PSA are evaluated for prostate cancer.
9.1 Pediatric and Geriatric Considerations¶
Adolescents may present with testicular germ cell tumors or bone metastases. Elderly patients often have comorbidities affecting treatment selection.
10. KEY POINTS & CLINICAL PEARLS¶
- Use IHC and molecular profiling to identify potential primaries. 2. Tailor chemotherapy based on histology and molecular markers. 3. PET-CT and genomic testing improve diagnostic accuracy. 4. Prognosis is poor for disseminated CUP, but targeted therapies offer hope. 5. Early detection of latent primaries ( ≤ 5%) is rare but possible.